Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.

• 冨樫, 庸介

• Masago, Katsuhiro

• Fukudo, Masahide

• Tsuchido, Yasuhiro

• Okuda, Chiyuki

• Kim, Young Hak

• Ikemi, Yasuaki

• Sakamori, Yuichi

• Mio, Tadashi

• Katsura, Toshiya

• Mishima, Michiaki

抄録

Recent reports indicate that refractory central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) are improved by high-dose gefitinib or erlotinib administration. We describe a Japanese woman with NSCLC and CNS metastases who was resistant to 75 mg daily erlotinib, but the metastases were improved by 150 mg daily erlotinib. We investigated the plasma and CSF concentrations of erlotinib at each dose as well as the correlation between the plasma and CSF concentrations of erlotinib.

収録刊行物

• Cancer chemotherapy and pharmacology

  Cancer chemotherapy and pharmacology 68 (4), 1089-1092, 2011-10

  Springer

キーワード

• Non-small cell lung cancer
• Epidermal growth factor receptor
• Tyrosine kinase inhibitor
• Erlotinib
• Central nervous system metastasis
• Cerebrospinal fluid

詳細情報

• CRID: 1050001335723604224
• NII論文ID: 120003534363
• NII書誌ID: AA00598397
• ISSN: 03445704
• HANDLE: 2433/150439
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • CiNii Articles